PSNL
Personalis Inc

2,632
Loading...
Loading...
News
all
press releases
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Tempus AI's PurIST test secures clinical validation, helping personalize treatment choices for advanced pancreatic cancer patients.
Zacks·22d ago
News Placeholder
More News
News Placeholder
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·2mo ago
News Placeholder
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks·2mo ago
News Placeholder
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·3mo ago
News Placeholder
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
chainwire·5mo ago
News Placeholder
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen's 45th Annual Health Care Conference on...
Business Wire·8mo ago
News Placeholder
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025...
Business Wire·8mo ago
News Placeholder
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG Annual MedTech, Digital Health, Life Science...
Business Wire·8mo ago
News Placeholder
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at Londons Francis Crick Institute and University College London, published new results from their...
Business Wire·9mo ago

Latest PSNL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.